Evidence map›Paper›PMID 36056765›Full record

ArticleDiabetes, obesity & metabolism2023

All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK.

Suping Ling, Francesco Zaccardi, Bogdan Vlacho, Ping Li, Jordi Real Gatius, Manel Mata-Cases, Josep Franch-Nadal, Mikhail N Kosiborod, Clare Gillies, Peter Fenici and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetes, obesity & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Cost-effectiveness of implementing the National Health Service England Diabetes Prevention Programme in Canada: a modelling study.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 5 countries.

Suping LingLeicester Diabetes Research Centre, University Hospital Leicester, Leicester General Hospital, Leicester, UK.ORCID 0000-0002-7207-5656
Francesco ZaccardiLeicester Diabetes Research Centre, University Hospital Leicester, Leicester General Hospital, Leicester, UK.
Bogdan VlachoDAP-Cat group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.ORCID 0000-0003-3768-8112
Ping LiInstitute for Clinical Evaluative Sciences (ICES), Burnaby, Canada.
Jordi Real GatiusCIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.
Manel Mata-CasesDAP-Cat group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.ORCID 0000-0003-3693-3622
Josep Franch-NadalDAP-Cat group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Mikhail N KosiborodSaint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.ORCID 0000-0002-3750-9789
Clare GilliesLeicester Diabetes Research Centre, University Hospital Leicester, Leicester General Hospital, Leicester, UK.
Peter FeniciAstraZeneca, Cambridge, UK.
Dídac MauricioDAP-Cat group, Unitat de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.ORCID 0000-0002-2868-0250
Baiju R ShahInstitute for Clinical Evaluative Sciences (ICES), Burnaby, Canada.ORCID 0000-0003-3598-3628
Kamlesh KhuntiLeicester Diabetes Research Centre, University Hospital Leicester, Leicester General Hospital, Leicester, UK.ORCID 0000-0003-2343-7099
University of Leicester · GBInstituto de Salud Carlos III · ESInstitute for Clinical Evaluative Sciences · CAInstitut Universitari d'Investigació en Atenció Primària Jordi Gol · ESSaint Luke's Hospital · USSunnybrook Health Science Centre · CAUniversità Cattolica del Sacro Cuore · ITUniversitat de Vic - Universitat Central de Catalunya · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo understand geographical and temporal patterns in the diabetes gap, the excess mortality risk associated with type 2 diabetes (T2D), in three high-income countries.

methodsUsing databases from Canada (Ontario), Spain (Catalonia) and the UK (England), we harmonized the study design and the analytical strategy to extract information on subjects aged over 35 years with incident T2D between 1998 and 2018 matched to up to five subjects without diabetes. We used Poisson models to estimate age-specific mortality trends by diabetes status and rate ratios and rate differences associated with T2D.

resultsIn more than 6 million people, 694 454 deaths occurred during a follow-up of 52 million person-years. Trends in all-cause mortality rates differed between Ontario and England; yet, the diabetes gaps were very similar in recent years: in 2018, we estimated 1.3 (95% confidence interval: 0.8, 1.8) and 0.8 (0.2, 1.5) more deaths per 1000 person-years in 50-year-old men with diabetes in Ontario and England, respectively, and 8.9 (6.1, 11.7) and 12.1 (9.1, 15.1) in 80-year-old men; between-country differences were small also in women. In Catalonia, rate ratios comparing T2D with no diabetes in men in 2018 were 1.53 (1.11, 2.11) at 50 years old, 0.88 (0.72, 1.06) at 60 years old, 0.74 (0.60, 0.90) at 70 years old and 0.81 (0.66, 1.00) at 80 years old, indicating lower mortality rates in men with T2D from the age of 60 years; rates were similar in women with and without diabetes at all ages. The diabetes gaps in cardiorenal mortality mirrored those of all-cause mortality: we observed consistent reductions in the proportions of cardiorenal deaths in subjects aged 80 years but variations in subjects aged ≤70 years, regardless of the presence of diabetes.

conclusionsBy reducing the confounding impact of epidemiological and analytical differences, this study showed geographical similarities and differences in the diabetes gap: an excess risk of all-cause and cardiorenal mortality in subjects with T2D is still present in Ontario and England in recent years, particularly in elderly subjects. Conversely, there were very small gaps in young men with T2D or even lower mortality rates in older subjects with T2D in Catalonia.

Indexed as

Diabetes Mellitus, Type 2AgedAged, 80 and overEnglandFemaleGeographyHumansMiddle AgedOntarioSpainall-cause mortalitycardiorenal mortalityelectronic health records datamultinational studytrend analysistype 2 diabetes

Identifiers

PMID36056765
PMCPMC10087715
OpenAlexW4294397820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.